MEI Pharma Executives

MEIPDelisted Stock  USD 3.07  0.18  6.23%   
MEI Pharma employs about 28 people. The company is managed by 17 executives with a total tenure of roughly 31 years, averaging almost 1.0 years of service per executive, having 1.65 employees per reported executive. Discussion of MEI Pharma's management performance can provide insight into the enterprise performance.
Daniel Gold  CEO
CEO and President and Director
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

MEI Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.2323) % which means that it has lost $0.2323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8974) %, meaning that it created substantial loss on money invested by shareholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
MEI Pharma maintains a total of 32.84 Million outstanding shares. MEI Pharma secures 7.6 % of its outstanding shares held by insiders and 8.12 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

MEI Pharma Workforce Comparison

MEI Pharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,010. MEI Pharma holds roughly 28.0 in number of employees claiming about 2.77% of equities under Health Care industry.

MEI Pharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MEI Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on MEI Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MEI Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

MEI Pharma Notable Stakeholders

A MEI Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MEI Pharma often face trade-offs trying to please all of them. MEI Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MEI Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Justin CPACFO CEOProfile
Daniel GoldCEO and President and DirectorProfile
Justin FileCFO SecretaryProfile
BA EsqCOO CounselProfile
Anne FreseChief OfficerProfile
Eugene ParkVP MarketingProfile
Virginia SankeyVP FinProfile
JD EsqChief OfficerProfile
Eric DengVP OperationsProfile
Richard GhalieChief OfficerProfile
MBA MDChief OfficerProfile
LLM JDSenior AffairsProfile
Robert MassChief Medical OfficerProfile
BA CPACFO SecProfile
Robert MDStrategic AdvisorProfile
Nicole IidaVice AffairsProfile
Yomara GomezNaidenSenior QualityProfile
String symbol = request.getParameter("s");

About MEI Pharma Management Performance

The success or failure of an entity such as MEI Pharma often depends on how effective the management is. MEI Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MEI management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MEI management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.

MEI Pharma Workforce Analysis

Traditionally, organizations such as MEI Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MEI Pharma within its industry.

MEI Pharma Manpower Efficiency

Return on MEI Pharma Manpower

Revenue Per Employee2.3M
Revenue Per Executive3.8M
Net Income Per Employee634.9K
Net Income Per Executive1M
Working Capital Per Employee1.2M
Working Capital Per Executive1.9M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Consideration for investing in MEI Stock

If you are still planning to invest in MEI Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MEI Pharma's history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Volatility Analysis
Get historical volatility and risk analysis based on latest market data